Jazz Pharmaceuticals Appoints Dr. Ted Love To Board Of Directors As Kenneth O’Keefe Announces Retirement

Jazz Pharmaceuticals plc  has announced the appointment of Ted W. Love, M.D., to its Board of Directors, effective December 1, 2025. Dr. Love brings over three decades of experience in drug development, commercialization, and executive leadership within the biotechnology sector. He most recently served as President and CEO of Global Blood Therapeutics, where he successfully led the company from its early stages to a global commercial organization before its acquisition by Pfizer in 2023.

"We are thrilled to welcome Ted to the Board," said Renee Gala, president and CEO, Jazz Pharmaceuticals. "His proven success in the biopharmaceutical industry and track record driving scientific innovation, commercial success and shareholder value will complement the capabilities of our existing Board as we deliver on our future growth strategy and deepen our commitment to innovating for patients."

Dr. Love’s previous roles include Executive Vice President of R&D and Technical Operations at Onyx Pharmaceuticals, and CEO/Chairman of Nuvelo, Inc. He began his career at Genentech, holding several management positions. A graduate of Haverford College with a B.A. in molecular biology and a medical degree from Yale, he also completed a residency in internal medicine and a cardiology fellowship at Massachusetts General Hospital. Currently, Dr. Love serves on the boards of Gilead Sciences, Royalty Pharma, and Structure Therapeutics, and is the Immediate Past Chair of BIO’s Board of Directors, contributing deep insights into policy, innovation, and patient access.

"I am impressed by the strength of Jazz's current business and future potential to support more patients with unmet medical needs," said Dr. Love. "I am excited to be joining Jazz at this pivotal moment for the Company, and to work with my colleagues on the Board and the management team to deliver on the Company's growth strategy and create sustained value for our shareholders, patients and employees."

The appointment supports Jazz’s ongoing board renewal initiative, with six new directors added over the past five years. Alongside this update, Kenneth O’Keefe has announced his retirement from the board, effective the same date. Mr. O’Keefe, who joined Jazz’s board in 2004, has been a longstanding member of the audit committee, previously serving as its chair. A co-founder of BPOC, LLC, a healthcare private equity firm, he remains active on several private healthcare company boards.

"In addition to welcoming Ted to our Board, I want to thank Ken for his service to Jazz and his incredible leadership over the years," said Bruce Cozadd, chairperson, Jazz Pharmaceuticals. "Ken has been a valued member of the Jazz Board during our journey from a small single product organization to a global biopharma company, contributing deep and thoughtful business and financial expertise as we grew and diversified our business. We have been grateful for his dedication and partnership and wish him well as he transitions off the Board."